# Generate Biomedicines Inc. (GENB) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $16.39, market value $2.1 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Generate Biomedicines Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 64.8×**. Each dollar of revenue is priced at 64.8×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 4.6×**. The shares trade at 4.6× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -11.7%**. Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -751.2%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -637.0%**. The company reported a net loss over the last twelve months.
- **Return on equity: 33.0%**. 33.0% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 25.1%**. Return on all capital, debt included, is 25.1%: comfortably above what that capital costs.
- **Return on assets: -67.5%**. Each dollar of assets produces -67.5% of profit.

## Growth
- **Revenue growth (1 yr): 55.9%**. Revenue grew 55.9% over the last year.
- **EPS growth (1 yr): -4.3%**. Earnings per share fell 4.3%, slower than revenue, so margins compressed.

## Financial health
- **Net debt / EBITDA: 0.7×**. It would take 0.7 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 2.85** (quick 2.85). Current assets cover the next year's liabilities 2.85 times.
- **Altman Z-score: -2.99**. A Z-score of -2.99 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Generate Biomedicines Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (5 analysts). 5 analysts cover Generate Biomedicines Inc.; the consensus is strong_buy, with an average price target of $26.00 (+59% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **From 52-week high: -27.7%** (49.0% above the low). Trading 28% below its 52-week high.
- **RSI (14-day): 54**. An RSI of 54 is neutral.
- **Beta (1 yr): 1.30** (volatility 89%). Beta of 1.30 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=GENB · Page: https://foliofundamentals.com/stocks/genb

Not investment advice.